These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9822984)

  • 41. Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation.
    Loumaye E; Engrand P; Shoham Z; Hillier SG; Baird DT
    Hum Reprod; 2003 Feb; 18(2):314-22. PubMed ID: 12571167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship of baseline ovarian volume to ovarian response in World Health Organization II anovulatory patients who underwent ovulation induction with gonadotropins.
    Lass A; Vassiliev A; Decosterd G; Warne D; Loumaye E
    Fertil Steril; 2002 Aug; 78(2):265-9. PubMed ID: 12137861
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation.
    Yong PY; Baird DT; Thong KJ; McNeilly AS; Anderson RA
    Hum Reprod; 2003 Jan; 18(1):35-44. PubMed ID: 12525438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon).
    Buckler HM; Robertson WR; Anderson A; Vickers M; Lambert A
    Hum Reprod; 1999 Dec; 14(12):2969-73. PubMed ID: 10601080
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exogenous hCG activity, but not endogenous LH activity, is positively associated with live birth rates in anovulatory infertility.
    Arce JC; Smitz J
    Hum Fertil (Camb); 2011 Sep; 14(3):192-9. PubMed ID: 21732905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of ovulation in polycystic ovary: human menopausal gonadotropin or human urinary follicle stimulating hormone?
    Venturoli S; Paradisi R; Fabbri R; Porcu E; Orsini LF; Flamigni C
    Int J Fertil; 1987; 32(1):66-70. PubMed ID: 2880819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of mifepristone on folliculogenesis in women treated with recombinant FSH.
    Messinis IE; Krishnan M; Kazem R; Khadilkar S; Templeton AA
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):309-14. PubMed ID: 9156040
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant FSH vs. urinary FSH for ovarian stimulation in in vitro fertilization.
    Meden-Vrtovec H; Mocnik-Roznik S; Tomazevic T; Virant-Klun I
    J Reprod Med; 2003 Oct; 48(10):799-803. PubMed ID: 14619648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Late low-dose pure follicle stimulating hormone for ovarian stimulation in intra-uterine insemination cycles.
    Balasch J; Ballescá JL; Pimentel C; Creus M; Fábregues F; Vanrell JA
    Hum Reprod; 1994 Oct; 9(10):1863-6. PubMed ID: 7844217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Timing of FSH administration for ovarian stimulation in normo-ovulatory women: comparison of an early or a mid follicular phase initiation of a short-term treatment.
    Cedrin-Durnerin I; Massin N; Galey-Fontaine J; Bry-Gauillard H; Roger M; Lahlou N; Hugues JN
    Hum Reprod; 2006 Nov; 21(11):2941-7. PubMed ID: 16877377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma inhibin levels during gonadotropin-induced ovarian hyperstimulation for IVF: a new index of follicular function?
    McLachlan RI; Robertson DM; Healy DL; de Kretser DM; Burger HG
    Lancet; 1986 May; 1(8492):1233-4. PubMed ID: 2872390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome.
    Filicori M; Cognigni GE; Taraborrelli S; Spettoli D; Ciampaglia W; de Fatis CT; Pocognoli P
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2659-63. PubMed ID: 10443656
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of follicular growth and production of a normal hormonal milieu in spite of using a constant low dose of luteinizing hormone in women with hypogonadotrophic hypogonadism.
    Shoham Z; Howles CM; Zalel Y; Weissman A; Insler V
    Hum Reprod; 1994 Mar; 9(3):431-6. PubMed ID: 7516348
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The safety and effectiveness of stepwise and low-dose administration of follicle stimulating hormone in WHO group II anovulatory infertile women: evidence from a large multicenter study in Spain.
    Balasch J; Tur R; Alvarez P; Bajo JM; Bosch E; Bruna I; Caballero P; Calaf J; Cano I; Carrillo E; Duque JA; Folguera G; de la Fuente A; Jiménez C; Laguens G; López E; Lozano A; Matarranz A; Moreno C; Nava J; Sanchis M; Temprano E; Ventura G; Peinado JA
    J Assist Reprod Genet; 1996 Aug; 13(7):551-6. PubMed ID: 8844311
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency.
    Imani B; Eijkemans MJ; Faessen GH; Bouchard P; Giudice LC; Fauser BC
    Fertil Steril; 2002 Jan; 77(1):83-90. PubMed ID: 11779595
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ovarian luteinizing hormone priming preceding follicle-stimulating hormone stimulation: clinical and endocrine effects in women with long-term hypogonadotropic hypogonadism.
    Balasch J; Fábregues F; Carmona F; Casamitjana R; Tena-Sempere M
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2367-73. PubMed ID: 19366842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease.
    Blankstein J; Rabinovici J; Goldenberg M; Shaley J; Mehta A; Serr DM; Mashiach S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone.
    De Placido G; Alviggi C; Mollo A; Strina I; Varricchio MT; Molis M
    Hum Reprod; 2000 Jan; 15(1):17-20. PubMed ID: 10611181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.